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Abstract
The aim of this meta-analysis was to investigate whether the blood concentrations of patients with multiple sclerosis (MS) are
associated with those of the healthy control group in terms of trace elements including zinc (Zn), iron (Fe), manganese (Mn),
magnesium (Mg), selenium (Se), and copper (Cu). A comprehensive search was performed in online databases including
PubMed, Scopus, Embase, and Web of Science for studies, which have addressed trace elements in MS up to July 23, 2020.
The chi-square test and I2 statistic were utilized to evaluate inter-study heterogeneity across the included studies. Weighted mean
differences (WMDs) and corresponding 95% CI were considered as a pooled effect size (ES). Twenty-seven articles (or 32
studies) with a total sample comprised of 2895 participants (MS patients (n = 1567) and controls (n = 1328)) were included.
Pooled results using random-effects model indicated that the levels of Zn (WMD= − 7.83 mcg/dl, 95% CI = − 12.78 to − 2.87, Z
= 3.09, P = 0.002), and Fe (WMD= − 13.66 mcg/dl, 95%CI = − 23.13 to − 4.19, Z = 2.83, P = 0.005) were significantly lower in
MS patients than in controls. However, it was found that levels ofMn (WMD= 0.03mcg/dl, 95%CI = 0.01 to 0.04, Z = 2.89, P =
0.004) were significantly higher in MS patients. Yet, no significant differences were observed in the levels of Mg, Se, and Cu
between both groups. This meta-analysis revealed that the circulating levels of Zn and Fe were significantly lower inMS patients
and that Mn level was significantly higher than those in the control group. However, it was found that there was no significant
difference between MS patients and controls with regard to levels of Mg, Se, and Cu.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelin-
ating disease of the central nervous system (CNS). Moreover,
it is considered the most common cause of neurological dis-
ability in young individuals [42]. This neurological T cell-
mediated autoimmune disease is characterized by inflamma-
tion, reactive astrogliosis, oligodendrocyte depletion, and de-
myelination in the brain, spinal cord, and optic nerve [41, 63].
Given that MS affects over 2.5 million people around the
world, the disease has turned into an urgent issue in healthcare
[13]. MS has three clinical subtypes which include relapsing-
remitting MS (RR-MS), primary progressive MS (PPMS),
and secondary progressive MS (SPMS) [19]. Despite the still
unknown etiology of the disease, it is clear that the interaction
between several immunologic, environmental, infectious, and
genetic factors account for the pathogenesis of MS [9].
Trace metals are involved in different MS-related patho-
physiological mechanisms [39]. Not only are they essential
for the synthesis and stability of myelin but they are also re-
quired for CNS to function normally [47]. As a trace element
which abounds in the human brain, zinc (Zn) comprises a group
of several major myelin proteins including myelin basic protein
(MBP) with important functional roles in myelin homeostasis,
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regulation of the immune system, and neuronal and oligoden-
drocyte death, hence its extensive role inMS pathogenesis [3, 8,
9]. Iron (Fe) is critical for normal neuronal metabolisms like
mitochondrial energy generation and myelination [30, 31].
However, the excessive iron levels in the brain may cause
iron-induced oxidative stress, thereby contributing to the neu-
rodegeneration seen in MS [65]. Manganese (Mn) is an essen-
tial trace element with essential roles in normal growth, as well
as in cellular homeostasis and development [17]. Despite its
importance, excessive levels of Mn are toxic to the CNS and
its implications in MS have been defined [39, 62].
In addition, having a significant effect on the nervous sys-
tem by decreasing the excitability of nerve cells [29], magne-
sium (Mg) increases the inhibitory effect and decreases the
stimulant effect of autonomic ganglia. Moreover, Mg ions
prevent excessive stimulation via competition with calcium
ions on the nerve endings [32]. Mg deficiency induces dys-
function in lymphocytes or nerve cells which is likely to be
implicated in the etiology of MS [11]. Likewise, it is believed
that oxidative stress plays a crucial role in the demyelination
pathogenesis and neurodegeneration in MS [23, 44].
Furthermore, as a potent antioxidant, selenium (Se) is not only
likely to have a positive effect on MS but also its deficiency
may be contributed to cell death and have some effects onMS
induction [51]. Likewise, copper (Cu) is involved in myelin
synthesis and has a significant role inmany neurodegenerative
diseases [3]. Moreover, it is shown that Cu plays a role in the
structure and function of several brain enzymes, as well as in
regulating neurotransmitters synthesis, iron metabolism, and
oxidative defense. The oxidative damage caused by excessive
copper accounts for the role of copper in MS pathology [27,
52, 61].
Previous studies evaluated the associations between the
homeostasis status of abnormal trace metals andMS, although
they obtained conflicting results. The present systematic re-
view and meta-analysis aimed to summarize the available
findings regarding the circulating levels of Zn, Se, Cu, Mg,
and Fe in MS patients and healthy controls.
Methods
The protocol for the review was registered with PROSPERO
(Provisional registration number: CRD42020204700). After
the search strategy was prepared, the online databases includ-
ing Web of Science (WOS), PubMed, Embase, and Scopus
were searched systematically up until July 23, 2020. The fol-
lowing MeSH (Medical Subject Headings) terms and key-
words were used for studies on MS and levels of common
trace element: [“Multiple sclerosis (MS)” AND “Trace ele-
ment” OR “Zinc (Zn)” OR “Iron (Fe)” OR “Manganese
(Mn) ” OR “Magnesium (Mg)” OR “Selenium (Se)” OR
“Copper (Cu)”]. The search strategy was supplemented for
the Scopus database with more details (Supplementary File.
S1). In addition, additional manual searches were conducted
according to the reference lists of previous reviews and eligi-
ble studies for further pertinent literature.
Study Selection
When the screening process was performed based on the titles
and abstracts, two independent authors (FM and SMAK) iden-
tified the eligible studies according to the inclusion and exclu-
sion criteria. Any discrepancy in the way the studies were
selected was resolved through discussion, resulting in a con-
sensus or consultation with a third author (HA).
Studies were selected in our meta-analysis if they (1) had
an original observational design (cross-sectional, case-control,
or cohort); (2) investigated the associations between the status
of trace elements of interest in both MS patients and controls
and,moreover, defined the diagnostic criteria forMS and trace
element measurement; (3) presented a sufficient amount of
data in order to extract or calculate the mean and standard
deviation (SD) for levels of at least a single trace element of
interest in both MS patients and controls; 4) were written in
English. Moreover, the exclusion criteria were animal studies,
reviews, case reports, case series, randomized controlled trials,
editorials, letters, abstracts without full texts, and studies with-
out controls or any insufficient data. Additionally, studies that
measured trace elements only in cerebrospinal fluid (CSF) or
in the whole blood, and those conducted without the inclusion
of any MS patients were also excluded.
Data Extraction and Quality Assessment
Standardized data collection sheets were used to extract the
following information: first author’s name, publication year,
the country where the study was conducted, study design,
sample size (MS patients/ controls), the main characteristics
of subjects, type of MS, the way the blood samples were
collected, measurement method for trace elements, and the
mean and SD levels of trace elements including Zn, Fe, Mn,
Mg, Se, and Cu in bothMS patients and controls. Two authors
(FM and SO) independently extracted data from the qualified
studies, which were then checked by a third author (EN) in
terms of data extraction accuracy. If an included study did not
directly report the SD in both groups, the equation listed in the
Cochrane handbook was used to calculate the SD from stan-
dard error of the mean (SEM), interquartile, or range for each
eligible study.
The Newcastle–Ottawa Scale (NOS) was applied to deter-
mine the risk of bias in the included studies. The three points
used for the purpose of critical appraisal included the selection
of subjects, comparability of included groups, and outcome/
exposure ascertainment. The NOS scores ranged from 0 to 9.
Depending on the type of study, quality scores ≥ 7 in case-
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control or cohort designs and ≥ 5 in cross-sectional designs
were considered as good quality (Table 1 and Supplementary
Table S1).
Statistical Analysis
All of the statistical analyses were conducted using the software
STATA 11.0 (STATA Corp, College Station, Texas). The mean
and SD of trace elements in both groups (MS patients/controls)
were used to pool the data. All measurements of trace elements
were converted to an equal unit (mcg/dl). Moreover, we consid-
ered weighted mean differences (WMDs) and the corresponding
95% CI as a pooled effect size (ES). The chi-square test and I2
statistic were utilized to evaluate inter-study heterogeneity across
the included studies. Likewise, in the presence of significant het-
erogeneity (with a P ≤ 0.1 for chi-square result with I2 value ≥
50%), a random-effects model, otherwise, a fixed-effect model
was used to combine ESs. Additional methods including sub-
group analyses (based on study design, region, type of MS, and
blood sampling) and sensitivity analyses were also performed to
identify the source of inter-study heterogeneity. Moreover, uni-
variate meta-regression analyses were conducted to assess if the
factors including publication year, total sample size, and quality
scoreswere associatedwith pooledESs. The quantitative statistics
including Egger’s linear regression test and Begg’s rank correla-
tion test were used to evaluate the potential evidence of publica-
tion bias across the included studies in the current meta-analysis.
Results
Literature Search and Study Characteristics
The PRISMA flow diagram for identification and selection of
studies in the present systematic review and meta-analysis are
shown in Fig. 1. The initial online search in the literature led to
the identification of 10,490 records (includes 893 from
PubMed, 3721 from Web of Science, 3579 from Scopus, and
2297 fromEmbase). Upon the removal of duplicate records, the
titles and abstracts for 7459 records were screened, leading to
the exclusion of 6497 studies. Based on the exclusion criteria
(as mentioned before), 962 full-text articles were assessed for
eligibility and 935 articles were excluded. Finally, 27 articles
(32 studies) were extracted to include in the current meta-
analysis [1, 2, 4, 7, 12, 14, 15, 20, 22, 24, 26, 28, 29, 33, 34,
36–38, 40, 43, 45, 49, 53, 55, 57–59, 62]. It is, moreover,
noteworthy that all 32 studies included 2895 participants
(1567 MS patients and 1328 control group participants).
These studies were conducted mainly in Europe and pub-
lished between 1980 and 2020. The included studies reported
the trace element levels of serum or plasma. Additionally, the
main characteristics of the qualified studies are displayed in
Table 1.
Main Outcomes
Figure 2 depicts the forest plots for the pooled estimates of the
weighted mean differences on trace elements between MS
patients and control groups.
Zn Among MS Patients and Controls
The results obtained from themeta-analysis, based on 17 qual-
ified studies using a random-effects model, indicated that Zn
levels were considerably lower in MS patients than in those of
the controls (WMD = − 7.83 mcg/dl, 95% CI = − 12.78 to −
2.87), along with considerable inter-heterogeneity (I2 =
99.0%, P < 0.001). The findings obtained from the subgroup
analyses demonstrated that the heterogeneity decreased within
some of subgroups. As observed in Table 2, the pooled effect
size did not significantly change in different study designs.
However, it was reported that Zn levels decreased in studies
conducted among MS patients in Europe (n = 7, WMD = −
11.09 mcg/dl, 95% CI = − 15.85 to − 6.34; I2 = 79.9%, P <
0.001), America (n = 5, WMD = − 5.34 mcg/dl, 95% CI = −
10.08 to − 0.60; I2 = 98.5%, P < 0.001), and Africa (n = 2,
WMD = − 15.44 mcg/dl, 95% CI = − 22.97 to − 7.91; I2 =
0.0%, P = 0.728). A stratification of studies based on the type
of MS revealed significant decreases in Zn Levels among
patients with other types of MS (n = 3, WMD = − 14.91
mcg/dl, 95% CI = − 18.03 to − 11.79; I2 = 0.0%, P =
0.931). Serum Zn reduced significantly among MS patients
compared with other blood sampling methods (n = 13, WMD
= − 10.52 mcg/dl, 95%CI = − 20.26 to − 0.78; I2 = 99.2%,P <
0.001). In addition, the meta-regression analysis indicated that
the total sample size across the included studies was negative-
ly related to the decreased zinc levels in MS patients (β = −
0.11, P = 0.026) (Table 3). The results of sensitivity analysis
also showed that the pooled WMD for Zn levels was stable
after the studies were excluded one by one (Supplementary
Fig. S1). Moreover, no potential evidence of publication bias
was observed across the qualified studies (P = 0.172 for
Egger’s test and P = 0.410 for Begg’s test).
Fe Among MS Patients and Controls
The pooled effect size from 12 qualified studies using a
random-effects model indicated that Fe levels in MS patients
were lower compared with those in the controls (WMD = −
13.66 mcg/dl, 95% CI = − 23.13 to − 4.19). Their P and I2 for
heterogeneity tests were statistically significant (I2 = 92.3%, P
< 0.001). The findings of subgroup analyses showed that the
heterogeneity decreased within some of the subgroups. As
shown in Table 2, in comparison with other regions, Fe levels
decreased in studies conducted among MS patients in Asia (n
= 3, WMD = − 9.98 mcg/dl, 95% CI = − 18.12 to − 1.84; I2 =
24.8%, P = 0.265). In addition, the subgroup analysis based
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on the type of MS indicated significantly decreased levels of
Fe in patients with no specific MS (n = 6, WMD = − 23.61
mcg/dl, 95% CI = − 42.42 to − 4.79; I2 = 90.8%, P = 0.016).
Furthermore, Fe levels were shown to be lower in studies with
case-control designs (n = 11,WMD= − 13.21mcg/dl, 95%CI
= − 23.00 to − 3.43; I2 = 92.9%, P <0.001) and in those with
serum blood sampling (n = 11, WMD = − 14.77 mcg/dl, 95%
CI = − 29.45 to − 0.08; I2 = 92.9%, P < 0.001). The results
obtained from the meta-regression analyses revealed that the
studied continuous factors did not have any statistically sig-
nificant effects on Fe concentrations (Table 3). Moreover, the
pooled findings for Fe remained constant in sensitivity analy-
sis (Supplementary Fig. S5). Begg’s test (P = 0.583) and
Egger’s test (P = 0.277) also were estimated to have no sig-
nificant evidence of publication bias.
Mn Among MS Patients and Controls
In accordance with four qualified studies which were pooled,
by using a random-effects model, meta-analysis results indi-
cated that Mn levels were higher in MS patients than in
controls (WMD = 0.03 mcg/dl, 95% CI = 0.01 to 0.04), along
with considerable inter-heterogeneity (I2 = 81.5%, P = 0.001).
As the number of included studies for this outcome was few,
additional analyses could not be conducted to assess the
source of inter-study heterogeneity. However, the included
studies for Mn were from Europe with a case-control design.
Likewise, the sensitivity analysis indicated that the exclusion
of the study by Ristori et al. [49] changed the pooled effect
size (WMD= 0.03, 95% CI − 0.00, 0.07). Moreover, it should
be noted that no potential evidence of publication bias was
found across the included studies (P = 0.174 for Begg’s test
and P = 0.449 for Egger’s test).
Mg Among MS Patients and Controls
Nine studies involving 857 subjects have reported Mg levels.
The finding of the meta-analysis conducted using a random-
effects model showed that Mg levels in MS patients were not
significantly different from those in control groups (WMD= −
182.91 mcg/dl, 95% CI = − 419.81 to 53.99). It is noteworthy
that additional analyses were conducted, along with the
Records idenfied through 
database searching 
(n = 10490): PubMed (893), Scopus 
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reported heterogeneity across the included studies (I2 =
97.7%, P < 0.001). With regard to the subgroup analyses
and meta-regression, no significant associations were found
between the levels of Mg and MS disease (Tables 2 and 3).
Based on the results of sensitivity analysis of the pooled
WMD forMg levels, we did not find any material change after
the studies were excluded one by one (Supplementary Fig.
S3). Likewise, no potential evidence of publication bias was
found across the included studies (P = 0.204 for Begg’s test
and P = 0.144 for Egger’s test).
Se Among MS Patients and Controls
The pooled WMD of eight qualified studies showed that Se
concentrations among patients with MSwere not significantly
different from those of the control group (WMD = − 0.19
mcg/dl, 95% CI = − 1.69 to 1.31). The results also revealed
considerable heterogeneity across the included studies (I2 =
92.5%, P < 0.001). The subgroups’ findings indicated that
none of the stratified subgroups was associated with Se con-
centrations (Table 2). However, the inter-heterogeneity is
NOTE: Weights are from random effects analysis
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Fig. 2 The forest plots of pooled
estimates of the weighted mean
differences on Zn (a), Se (b), Mg
(c), Cu (d), Fe (e), Mn (f) between
MS patients and control groups
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deceased in some strata. Based on the results obtained from
meta-regression analyses, the studied continuous factors did
not have any statistically significant effects on Se concentra-
tions (Table 3). Moreover, the pooled findings remained con-
stant in sensitivity analyses (Supplementary Fig. S2). The re-
sults of Egger’s test (P = 0.155) and Begg’s test (P = 0.188)
showed that there was no publication bias.
Cu Among MS Patients and Controls
Eleven studies comprised of 507MS patients and 540 controls
have investigated Cu levels. According to their pooled results,
Cu concentrations were not significantly different between the
two groups (MS patients/controls) (WMD = 14.06 mcg/dl,
95% CI = − 7.60 to 35.71). However, it was shown that there
NOTE: Weights are from random effects analysis
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Table 2 Findings of subgroup analyses
Outcomes Number of studies WMD (95% CI) I2 and P-value
Zn (mcg/dl) Total 17 − 7.83 (− 12.78, − 2.87) 99.0%, P < 0.001
Study design Case-control 14 − 6.52 (− 11.80, − 1.25) 99.1%, P < 0.001
Cohort 3 − 13.52 (− 25.02, − 2.01) 92.1%, P < 0.001
Cross-sectional - - -
Region Europe 7 − 11.09 (− 15.85, − 6.34) 79.9%, P < 0.001
Asia 3 0.43 (− 35.87, 36.72) 99.5%, P < 0.001
America 5 − 5.34 (− 10.08, − 0.60) 98.5%, P < 0.001
Africa 2 − 15.44 (− 22.97, − 7.91) 0.0%, P = 0.728
Type of MS Non-specific MS 13 − 5.25 (− 10.67, 0.17) 99.1%, P < 0.001
RR-MS 1 − 21.60 (− 30.00, − 13.20) -
Other 3 − 14.91 (− 18.03, − 11.79) 0.0%, P = 0.931
Blood sampling Serum 13 -10.52 (-20.26, -0.78) 99.2%, P < 0.001
Plasma 4 0.06 (− 6.80, 6.91) 89.8%, P < 0.001
Fe (mcg/dl) Total 12 − 13.66 (− 23.13, − 4.19) 92.3%, P < 0.001
Study design Case-control 11 − 13.21 (− 23.00, − 3.43) 92.9%, P < 0.001
Cohort - - -
Cross-sectional 1 − 21.23 (− 49.62, 7.16) -
Region Europe 8 − 18.48 (− 40.36, 3.41) 94.2%, P < 0.001
Asia 3 − 9.98 (− 18.12, − 1.84) 24.8%, P = 0.265
America - - -
Africa 1 − 0.03 (− 3.21, 3.15) -
Type of MS Non-specific MS 6 − 23.61 (− 42.42, − 4.79) 90.8%, P = 0.016
RR-MS 4 0.72 (− 7.75, 9.18) 61.0%, P = 0.053
Other 2 − 22.51 (− 101.01, 55.98) 97.5%, P < 0.001
Blood sampling Serum 11 − 14.77 (− 29.45, − 0.08) 92.9%, P < 0.001
Plasma 1 − 6.36 (− 9.11, − 3.60) -
Mg (mcg/dl) Total 9 − 182.91 (− 419.81, 53.99) 97.7%, P < 0.001
Study design Case-control 8 − 160.83 (− 415.13, 93.48) 97.9%, P < 0.001
Cohort 1 − 350.00 (− 496.11, 203.89) -
Cross-sectional - - -
Region Europe 6 − 3.01 (− 120.07, 114.04) 75.0%, P = 0.001
Asia 3 − 498.17 (− 1305.42, 309.08) 99.4%, P < 0.001
America - - -
Africa - - -
Type of MS No specific MS 6 − 75.75 (− 272.78, 121.28) 90.1%, P < 0.001
RR-MS - - -
Other 3 − 382.81 (− 1051.10, 285.47) 99.3%, P < 0.001
Blood sampling Serum 7 7.70 (− 91.87, 107.27) 83.8%, P < 0.001
Plasma 2 − 808.55 (− 1679.93, 62.83) 97.9%, P < 0.001
Se (mcg/dl) Total 6 − 0.19 (− 1.69, 1.31) 92.5%, P < 0.001
Study design Case-control 3 − 0.37 (− 3.12, 2.38) 96.7%, P < 0.001
Cohort 3 − 0.29 (− 0.96, 0.38) 0.0%, P = 0.469
Cross-sectional - - -
Region Europe 5 − 0.09 (− 2.06, 1.88) 93.9%, P < 0.001
Asia - - -
America 1 − 0.55 (− 1.34, 0.24) -
Africa - - -
Type of MS No specific MS 3 0.25 (− 1.81, 2.31) 93.1%, P < 0.001
RR-MS 1 − 2.40 (− 3.00, − 1.80) -
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was significant inter-heterogeneity across the included studies
(I2 = 99.7%,P < 0.001). Moreover, subgroups’ findings on the
association between MS disease and Cu levels remained in-
significant in different strata of study testing, type of MS, and
blood sampling (Table 2). However, the stratification of stud-
ies based on the region wherein they were performed revealed
significant increases in Cu levels among patients in Europe (n
= 8, WMD = 11.09 mcg/dl, 95% CI = 1.92 to 20.26; I2 =
97.3%, P < 0.001). In addition, the meta-regression analysis
showed that the studied continuous factors had no significant
effect on the association between MS and Cu levels (Table 3).
Yet, the pooled WMD in sensitivity analysis remained con-
stant after each study, which addressed the association be-
tween the two groups, was excluded (Supplementary Fig.
S4). There was no statistically potential publication bias using
Begg’s test (P = 0.578) and Egger’s test (P = 0.938).
Discussion
MS is the most frequent chronic inflammatory demyelinating
disease of the CNS. It is characterized by autoimmunity and
Table 2 (continued)
Outcomes Number of studies WMD (95% CI) I2 and P-value
Other 2 0.38 (− 0.89, 1.65) 0.0%, P = 0.879
Blood sampling Serum 4 − 0.92 (− 2.26, 0.43) 82.0%, P < 0.001
Plasma 2 0.99 (− 2.08, 4.06) 95.1%, P < 0.001
Cu (mcg/dl) Total 11 14.06 (− 7.60, 35.71) 99.7%, P < 0.001
Study design Case-control 9 19.66 (− 4.48, 43.81) 99.8%, P < 0.001
Cohort 2 − 13.35 (− 35.71, 9.01) 78.4%, P = 0.031
Cross-sectional - - -
Region Europe 8 11.09 (1.92, 20.26) 97.3%, P < 0.001
Asia 2 31.07 (− 74.97, 137.10) 99.8%, P < 0.001
America 1 0.00 (− 19.53, 19.53) -
Africa
Type of MS No specific MS 7 19.03 (− 22.60, 60.66) 99.5%, P < 0.001
RR-MS 3 8.21 (− 5.48, 21.90) 98.7%, P < 0.001
Other 1 − 1.40 (− 6.77, 3.97) -
Blood sampling Serum 9 11.35 (− 12.63, 35.33) 99.8%, P < 0.001
Plasma 2 26.75 (− 24.59, 78.09) 94.9%, P < 0.001
Table 3 Findings of meta-
regression analyses Outcomes Continues factors Coefficient 95% CI P-value tau2 Adj R-squared
Zn (mcg/dl) Publication year − 0.46 − 1.03, 0.12 0.114 219.8 10.20%
Total sample size − 0.11 − 0.20, − 0.01 0.026 184 24.82%
Quality scores − 3.90 − 12.51, 4.72 0.350 244 0.31%
Fe (mcg/dl) Publication year 0.15 − 3.15, 3.45 0.922 866 − 11.16%
Total sample size − 0.32 − 0.67, 0.02 0.064 548.5 29.60%
Quality scores − 1.65 − 23.52, 20.22 0.870 870.7 − 11.75%
Mg (mcg/dl) Publication year 12.58 − 32.10, 57.27 0.527 214753 − 7.97%
Total sample size 3.17 − 3.29, 9.62 0.284 189228 4.87%
Quality scores 295.85 − 214.84, 806.55 0.213 174672 12.18%
Se (mcg/dl) Publication year − 0.09 − 0.24, 0.07 0.193 2.08 24.94%
Total sample size − 0.02 − 0.05, 0.01 0.168 1.94 30.07%
Quality scores − 1.27 − 2.81, 0.28 0.085 1.39 50.32%
Cu (mcg/dl) Publication year 1.05 − 1.12, 3.21 0.301 969 2.29%
Total sample size 0.07 − 0.42, 0.56 0.760 1091 − 9.98%
Quality scores − 3.77 − 32.54, 24.99 0.773 1089 − 9.82%
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neurodegeneration, leading to irreversible and severe clinical
disability [18, 21]. Among the environmental factors, abnor-
malities of trace elements have been hypothesized to be in-
volved in the pathogenesis of various neurologic diseases,
including MS [2, 49]. This systematic review and meta-
analysis aimed to ascertain if the blood concentrations of pa-
tients with MS and healthy adults are different in terms of Zn,
Fe, Mn, Mg, Se, and Cu. Findings obtained from the present
meta-analysis revealed significantly lower circulating levels
of Fe and Zn among patients with MS in comparison with
the healthy controls. However, trace elements of Cu and Se
were not significantly different between MS patients and con-
trols. With respect to Mg, there was no significant difference
between the two groups.
Zinc is an essential trace element in the brain and a cofactor
of more than 300 enzymes including matrix metalloprotein-
ases (MMPs). It is a component of many proteins such as
myelin basic protein. Thus, it plays a significant role in MS
pathophysiology [5, 45, 60]. Our findings of considerably
lower serum Zn levels in MS patients compared to controls
are in line with some previous studies. A previous meta-
analysis reported a significant reduction in overall serum/
plasma Zn levels in patients withMS compared to the controls
[6]. Moreover, in a cohort study, it was revealed that MS
diagnosis is associated with lower serum zinc concentrations
compared to the controls, but without marked zinc deficiency.
This cohort study also declared that lower zinc levels in MS
patients could be a result of enhanced upregulation of zinc-
dependent MMPs, with higher levels during the active disease
stage. Likewise, this upregulation might explain the reported
lower zinc levels in RR-MS patients compared to patients with
chronic disease [45]. Subsequent to the subgroup analyses, the
observed heterogeneity decreased within some of the sub-
groups, including European and RR-MS ones. It should be
noted that Europeans showed lower Zn levels in MS patients
compared to controls, implying the need for further investiga-
tions to explore the reason behind Zn deficiency in patients
suffering from MS in this region. Moreover, zinc levels were
demonstrated to be significantly lower in RR-MS subgroups
compared with other types. It is highly recommended that
more cohort and clinical trial studies be conducted to assess
Zn therapy in RR-MS patients, as a more common type of
MS.
Fe is a cofactor of various enzymes for normal brain me-
tabolisms [30, 31]. Abnormal Fe homeostasis may contribute
to neurodegeneration which is relevant to the pathology of
MS. Findings obtained from the present study are consistent
with recent works as they revealed that the MS group had
considerably lower Fe values in comparison with healthy con-
trols [4]. Iron is considered a key factor in MS pathogenesis,
as it may lead to neuronal damage through triggering oxida-
tive stress [35]. Fe subgroup analyses showed lower hetero-
geneity within different geographical subgroups. In this
regard, Asians showed significantly lower circulating levels
of Fe in comparison with other regions. Therefore, studies that
are more comprehensive are needed to clarify the observed
iron deficiency in Asian patients with MS.
Mn serves as a cofactor for maintaining the function and
regulation of many biochemical and cellular reactions, includ-
ing multiple enzymes, which are critical for synthesis and
metabolism of neurotransmitters and neuronal and glial func-
tion [16, 25]. It is also recognized as a neurotoxicant through
the formation of hydroxyl radicals that decreases cellular an-
tioxidants and offers crucial implications for MS [56]. Our
meta-analysis results indicated, based on four qualified stud-
ies, that Mn levels were significantly higher in MS patients
than in controls with high heterogeneity. Therefore, further
studies with a larger sample size are required to explain the
exact implication of Mn in patients with MS.
Mg has a key role in the nervous system by reducing the
excitability of nerve cells [32]. Mg activates about 320 en-
zymes and interacts with other minerals, such as calcium, zinc,
and aluminum, affecting the immune system and the content
of these elements in the central nervous system [64]. Mg de-
ficiency impairs antioxidant defense through decreased activ-
ity of Cu/Zn superoxide dismutase and reduced glutathione
synthesis. It also increases synthesis or activity of injurious
mediators, e.g., tumor necrosis factor (TNF), interleukin 6 (IL-
6), IL-1, oxygen-free radicals, and endothelin, thereby being
possibly implicated in the etiology ofMS [29].With respect to
Mg, no significant difference was found between the two
groups in the present meta-analysis. In a previous study on
RR-MS patients, the average serum level of Mg was normal,
but certain abnormalities were observed, due to a high number
of MS patients represented a dysregulated serum Mg. As pa-
tients with a deficiency and an excess of serum Mg levels had
a worse clinical condition, Mg supplementation should be
taken after the concentration of this element in the serum is
evaluated [29]. Moreover, more studies with a larger sample
size are required to explain the exact role played by Mg in the
pathophysiology of MS.
Se is another important trace element that is well known for
its key role in the glutathione peroxidase enzyme and its anti-
inflammatory effect [3]. Because of its potent antioxidant and
anti-inflammatory properties, Se may have a protective effect
on the course of MS. Therefore, it is frequently claimed that
Se deficiency is a common and important issue in MS [51]. In
this study, no statistically significant difference was shown
between MS patients and controls in terms of their circulating
levels of Se, though MS patients demonstrated a lower Se
level compared to the control group.
Cu is involved in the structure and function of several brain
enzymes, oxidative defense, iron metabolism, regulating neu-
rotransmitters, andmyelin synthesis [10]. Cu is also crucial for
the normal development of the nervous system [59]. The role
of Cu in MS pathology is shown to be through its excessive
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concentrations and subsequent oxidative damage. Therefore,
Cu levels should be precisely adjusted for essential enzyme
activity and prevention of oxidative stress [54]. Based on the
present study, no statistically significant difference was found
between MS patients and controls in terms of Cu trace ele-
ment. However, given higher Cu levels in MS patients, the
assumption that higher circulating levels of Cumay contribute
to MS development is unclear. A recent meta-analysis also
showed a higher concentration of Cu inMS patients compared
to the healthy controls [50]. The differences between the re-
sults of these meta-analyses may be due to the method used to
determine pooled effect size. These findings confirm the pos-
sible function of Cu inMS etiology and could stimulate future
studies with longitudinal designs and larger sample sizes.
It should be noted that this meta-analysis had several lim-
itations that should be taken into account. First, given the high
heterogeneity of the selected studies, the obtained results
should be interpreted with caution. Next, it is likely that the
associations reported in the present meta-analysis are affected
by participants’ gender, age, and/or expanded disability status
scale (EDSS) scores that are not addressed in this meta-anal-
ysis. This is because the included articles lacked detailed re-
spective information. Furthermore, most of the included stud-
ies of this meta-analysis did not take account of the confound-
ing factors including smoking, alcohol, lifestyle habits, and
dietary intake of trace elements. Accordingly, the aforemen-
tioned factors are to be addressed in subsequent studies
assessing the association between the level of trace elements
and MS. A strength of this meta-analysis would be the pooled
result of the minerals that permits a precise assessment of the
relationship between the circulating levels of the trace ele-
ments and MS. To identify the possible sources of heteroge-
neity in our study, a subgroup analysis was conducted.
Likewise, since no publication bias was detected, it is likely
that the obtained results are not biased. Notably, iodine (I) was
considered as a trace element in our search, although no article
was found to report the role of this element in MS.
Conclusion
This meta-analysis revealed that patients with MS had lower
Zn and Fe as compared with the controls. Mn levels were
significantly higher in MS patients than in the controls. In
addition, Fe and Zn levels were influenced by the region and
disease subtypes. However, it was also shown that MS pa-
tients were not significantly associated in terms of Se, Mg,
and Cu. It is suggested that additional, larger, and well-
designed clinical studies, especially on iodine and other trace
elements with lower available evidence, could produce invalu-
able results in the context of MS. Given the substantial het-
erogeneity among the included studies, the results should be
treated with caution. Finally, the identification of potential
nutritional supplements such as trace elements may provide
valuable insights into the treatment options for MS, especially
for patients in whom disease-modifying drugs do not prevent
disease progression or nutritional deficiencies are prevalent.
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